ACHIEVE-4 Trial: Oral Orforglipron Shows Cardiac Safety

The Phase 3 ACHIEVE-4 trial demonstrated that once-daily oral orforglipron is cardiovascularly safe.

Eli Lilly Reports Topline ACHIEVE-4 Trial Results

Eli Lilly and Company has announced positive topline results from its Phase 3 ACHIEVE-4 clinical trial, demonstrating that once-daily oral orforglipron—recently approved under the brand name Foundayo—is non-inferior to insulin glargine in terms of cardiovascular safety. The trial represents a major milestone in the clinical development of Lilly's new small-molecule oral GLP-1 agonist, which was approved by the FDA on April 1, 2026, for chronic weight management.

The ACHIEVE-4 trial (NCT05803421) was designed to evaluate the cardiovascular safety and metabolic efficacy of orforglipron in patients with Type 2 diabetes and high cardiovascular risk. The study reached completion in mid-March 2026, and the newly published topline results confirm the drug's favorable safety profile. Patients interested in supervised treatment options can explore tirzepatide and oral GLP-1 options online.

Orforglipron: A Small-Molecule Oral GLP-1 Agonist

Orforglipron (Foundayo) is a daily, non-peptide small-molecule GLP-1 receptor agonist. GLP-1 receptor agonists are a class of medications that mimic the satiety hormone glucagon-like peptide-1, helping patients manage blood sugar levels and achieve weight loss. Unlike first-generation oral GLP-1 options, orforglipron is a small molecule, which allows for stable absorption in the gastrointestinal tract without strict food or water intake restrictions.

This formulation allows patients to take the medication daily with or without food, providing greater convenience compared to injectables or oral semaglutide, which requires fasting. Clinicians view this convenience as a primary driver of long-term patient adherence. As oral options expand, understanding cost structures is vital; patients can review current weight care pricing online to compare treatments.

Cardiovascular Outcomes and Mortality Rate Comparisons

The primary endpoint of the ACHIEVE-4 trial was the time to first occurrence of major adverse cardiovascular events, measured as a four-point composite (MACE-4) including cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, or hospitalization for unstable angina. The study successfully demonstrated that orforglipron is non-inferior to insulin glargine in cardiovascular risk, with a hazard ratio of 0.84 (95% CI: 0.59–1.20).

Additionally, pre-planned exploratory analyses revealed a statistically significant survival benefit, showing a 57% lower risk of all-cause mortality in the orforglipron group compared to the insulin glargine cohort (hazard ratio: 0.43; 95% CI: 0.25–0.75). While the primary focus was safety, these survival outcomes suggest that orforglipron offers systemic cardiorenal benefits that could improve long-term prognosis in high-risk diabetic populations. Further trials are ongoing to confirm these findings.

Glycemic Control and Weight Loss Improvements

In addition to meeting its primary safety endpoint, orforglipron demonstrated superior metabolic efficacy compared to insulin glargine at 52 weeks. Patients treated with once-daily oral orforglipron achieved a mean A1C reduction of 1.6%, compared to a 1.0% reduction in the insulin glargine group. This superior glycemic control was achieved with a significantly lower risk of hypoglycemia, a common side effect of insulin therapy.

Furthermore, the orforglipron group experienced substantial weight loss, with participants losing an average of 8.8% of their body weight (–8.1 kg) at 52 weeks, compared to an average weight gain of 1.7% (+1.4 kg) in the insulin glargine cohort. This weight-loss benefit is highly relevant for patients with Type 2 diabetes, as weight reduction is a primary clinical target to improve insulin sensitivity and reduce cardiovascular risk. To check clinical eligibility, patients can qualify online.

Clinical Implications for Oral Weight Care Accessibility

The positive results from the ACHIEVE-4 trial are expected to accelerate the clinical adoption and regulatory support for oral weight care. By proving that orforglipron is both cardiovascually safe and superior in metabolic control to insulin, the trial establishes oral daily tablets as a viable alternative to injectables for high-risk patients. This could significantly expand the pool of patients who can safely access advanced metabolic therapies.

Eli Lilly plans to use the ACHIEVE-4 data to support regulatory submissions for the Type 2 diabetes indication globally. As PBMs begin to expand coverage for Foundayo, the availability of a daily oral option without food restrictions could reshape the competitive landscape of the obesity and diabetes markets. Clinicians will continue to monitor real-world safety data as more patients adopt this new treatment option.

This article is for informational purposes only and is not medical advice. Consult your healthcare provider before starting any weight loss medication or treatment.